Qure.ai

About Qure.ai

Financials

Dated, source-cited figures. Estimates are marked.

Products by Qure.ai

All products by Qure.ai reviewed by our AI panel of experts.

Qure.aiAI Healthcare

AI-powered medical imaging for tuberculosis, lung cancer, and stroke care

Free7.6/10

How Our Review Panel Scores Qure.ai

Six independent reviewer personalities assessed Qure.ai's product on their own terms. They disagreed by 2.5 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Qure.ai competes with, and how they differ.

Aidoc7.8/10

Aidoc's CT-only triage platform flags a broad catalog of acute findings (PE, ICH, C-spine fracture) mainly for US hospital systems, while Qure.ai leads with chest X-ray (qXR) alongside CT and pushes further into low-resource and emerging-market deployments for TB and lung-cancer screening.

1 product reviewed on TopReviewed

Viz.ai8.0/10

Viz.ai is built around a clinician-notification and care-coordination workflow for stroke, pulmonary embolism and aortic disease across hospital networks, whereas Qure.ai's qXR/qER products are point-of-read detection algorithms embedded directly into the radiology report.

1 product reviewed on TopReviewed

Lunit7.9/10

Lunit, listed on South Korea's KOSDAQ, concentrates on cancer screening (chest X-ray, mammography) plus pathology biomarker analysis, while Qure.ai's line spans chest X-ray, head CT and ultrasound triage across a broader set of critical-care indications including TB and stroke.

1 product reviewed on TopReviewed

Enlitic7.5/10

Enlitic's platform focuses on standardizing and prioritizing incoming imaging data across a radiology department's worklist rather than issuing standalone diagnostic findings, contrasting with Qure.ai's FDA-cleared detection algorithms for specific pathologies.

1 product reviewed on TopReviewed

Butterfly Network8.1/10

Butterfly Network is a hardware company selling its own handheld Butterfly iQ ultrasound probe with built-in AI guidance, while Qure.ai is software-only, integrating its AI into third-party X-ray and CT scanners (and, via a 2026 Gates Foundation grant, point-of-care ultrasound).

1 product reviewed on TopReviewed

Company Timeline

Key milestones in Qure.ai's history, with sources.

1. Feb 26, 2026Milestone

   qXR-Detect earns FDA clearance across six chest X-ray indications

   The FDA cleared six new indications (lung, pleura, mediastinum/hila & heart, bone, hardware, other) for Qure.ai's qXR-Detect, bringing the company's total to 26 FDA clearances across 9 products.

   itnonline.com
2. Nov 18, 2025Partnership

   Partners with Microsoft to expand US access to lung cancer AI suite

   Qure.ai and Microsoft announced a partnership to increase US access to Qure.ai's lung cancer detection and management suite.

   qure.ai
3. Oct 22, 2025Milestone

   Receives 19th FDA clearance, for AI detection of large vessel occlusion on CTA

   Qure.ai received its 19th FDA clearance, covering AI-based detection of large vessel occlusions on CT angiography scans, continuing its US regulatory expansion.

   qure.ai
4. Jun 27, 2025Milestone

   Named to TIME's 100 Most Influential Companies of 2025

   Qure.ai was recognized among TIME Magazine's 100 Most Influential Companies of 2025.

   qure.ai
5. Sep 25, 2024Funding

   Raises $65M Series D led by Lightspeed and 360 ONE Asset

   Qure.ai closed a $65 million Series D round led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund, Novo Holdings, HealthQuad, Kae Capital and TeamFund, to fund US expansion and foundational AI model development.

   hitconsultant.net
6. Jun 25, 2024Funding

   Receives strategic investment from Merck Global Health Innovation Fund

   Merck Global Health Innovation Fund made a strategic investment in Qure.ai to support innovation in healthcare AI; the amount was not disclosed.

   qure.ai
7. Mar 29, 2022Funding

   Raises $40M funding round led by Novo Holdings and HealthQuad

   Qure.ai raised $40 million in a round led by Novo Holdings and HealthQuad, with support from existing investor MassMutual Ventures, to fund US/Europe expansion and product development for critical care and community diagnostics.

   novoholdings.dk
8. Jun 30, 2020Milestone

   qER wins industry's first FDA 4-in-1 clearance for medical imaging AI

   Qure.ai's qER head-CT triage tool received what the company called the industry's first 4-in-1 FDA clearance, covering intracranial bleeds, mass effect, midline shift and cranial fractures; two of the four capabilities were exclusive to Qure.ai at the time.

   itnonline.com
9. February 2020Funding

   Raises $16M funding round led by Sequoia India and MassMutual Ventures Southeast Asia

   Qure.ai raised $16 million in a round led by Sequoia India and MassMutual Ventures Southeast Asia.

   entrackr.com
10. 2016Founded

    Qure.ai founded by Prashant Warier

    Qure.ai was founded in Mumbai in 2016 by Prashant Warier (Founder & CEO) to apply artificial intelligence to make healthcare diagnostics more accessible and affordable.

    qure.ai